IntegraGen, a company specialized in the deciphering of the human genome and the development of diagnostic tools in cancerology, announces that it has been awarded the Galien MedStartUp 2017 prize in the category of "Best Collaborations in Innovative Therapies and Diagnostics" for its ICE project during the MedStartUp conference held in New York. A software created to optimize the diagnosis of patients with very serious diseases in order to define more targeted and better adapted treatments.
Ahe partnership with The Solution Lab concerns the American market launch of the software developed by IntegraGen, "ICE" (Interpretation of Clinical Exome). This software was designed to provide clinicians with an interpretation tool that facilitates the analysis of genomic data from cancer sequencing. The objective of the ICE project is to improve the diagnosis of cancer patients and to develop an approach guided by exome and transcriptome sequencing data in order to identify targeted therapy options for these patients. This project brings together IntegraGen, Gustave Roussy, a European leader in the fight against cancer, Sogeti High Tech, a subsidiary of the Capgemini Group, and INSERM. A partnership that combines the skills that all these organizations possess together in the fields of oncology, sequencing, data processing, software development and clinical interpretation of sequencing results.
Through this tool, personalized medicine becomes accessible.
"The massive influx of tumor sequencing data makes it essential to develop tools to isolate from the tens of gigabytes of data produced for a patient, those that have real clinical repercussions and an impact on patient management. Access to sequencing data for all of a patient's coding genes requires an in-depth review of how the results are used and automated interpretation assistance, without which the data will not be usable and compatible with cancer patient management timelines. said Professor Eric Solary, Director of Research at Gustave Roussy.
For Dr. Bernard Courtieu, Chairman and CEO, IntegraGen, "Sequencing has been revolutionized by the advent of so-called massively parallel technologies that have dramatically reduced the cost and time to generate data. The bottleneck is now the management of the tens of gigabytes involved in sequencing a patient's tumour exome and transcriptome. ICE will enable clinicians to treat patients based on the biological specifics of their tumor."
"We are honored to receive this prestigious award from the Galician Foundation", said Larry Yost, General Manager of IntegraGen, Inc." Thanks to this collaboration with The Solution Lab, we have obtained direct feedback from American players that allows us to understand the market dynamics and prepare the strategy for marketing and launching the software on the American territory. ”
"Our collaboration with IntegraGen focused on the need for powerful and easy-to-use software tools that enable clinicians to analyze genomic data from cancer patients, added Stefanie Mazlish, CEO of The Solution Lab. "Our experts have analyzed market opportunities, gathered feedback from a number of opinion leaders and established recommendations on the positioning and launch of the software, specifically for the US market."
For the fourth year, the MedStartUp initiative, created by the Fondation Galien and Business France, rewards the best partnerships between French startups/SMEs and American healthcare companies for the development of breakthrough innovations in the field of biotechs and medtechs.
More information on : www.integragen.com
Source : Business Wire, 30/10/2017
